Unpublished conference/Abstract (Scientific congresses and symposiums)
EPILEPSY AND THE SV2A PROTEIN: new insights about the disease.
Serrano Navacerrada, Maria Elisa; Raedt, Robrecht; Becker, Guillaume et al.
201820TH EURON PhD DAYS
 

Files


Full Text
PhD_Euron_Abstract__SerranoME_2018.pdf
Author preprint (181.32 kB)
Abstract
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
epilepsy; sv2a; preclinical imaging; microPET; fluorine-18; UCB-H
Abstract :
[en] Around two million of people worldwide are affected by neurodegenerative diseases, such as Alzheimer, Parkinson or Epilepsy. Despite the social and the economic impact of these diseases, their causes still remain unclear. In the case of the epilepsy, for example, around 25% of the patients suffer drug-resistant epilepsy, for which there is no medicament able to mitigate the epileptic crises or the associated symptomatology, such as cognitive problems and mood disorders. In 1974, UCB Pharma synthetized a new antiepileptic drug with a high therapeutic index: the Levetiracetam. The target of this medicament is the Synaptic Vesicle Protein 2A (SV2A) whose specific role in the pathology is still unknown. The main goal of my thesis is to better understand the relationship between this protein and the epilepsy. On the one hand, the production and phenotyping of conditional knockout mice for the SV2A protein allowed us to discover a possible implication of this protein in the spatial memory and anxiety process, an important part of the epileptic symptomatology. On the other hand, the synthesis of the radiotracer [18F]UCB-H, with a high affinity for the SV2A protein, enabled the in vivo evaluation (with the mPET technique) of a rat model of the temporal lobe epilepsy through the disease process. Results showed a strong correlation between the severity of the epilepsy (EEG technique) and the SV2A levels in different brain regions, highlighting the importance of this protein in the development of the disease. In summary, although further studies in humans are necessary, this protein emerges as an important key in clinical diagnosis and medical research, being implicated in all the aspects of the epileptic disease.
Research center :
GIGA CRC (Cyclotron Research Center) In vivo Imaging-Aging & Memory - ULiège
Disciplines :
Radiology, nuclear medicine & imaging
Author, co-author :
Serrano Navacerrada, Maria Elisa ;  Université de Liège - ULiège > Preclinical Imaging
Raedt, Robrecht
Becker, Guillaume ;  Université de Liège - ULiège > Département de Psychologie > Département de Psychologie
Bahri, Mohamed Ali  ;  Université de Liège - ULiège > Aging & Memory
Mievis, Frédéric ;  Université de Liège - ULiège > Centre de recherches du cyclotron
Lemaire, Christian ;  Université de Liège - ULiège > Radiochemistry
Giacomelli, Fabrice ;  Université de Liège - ULiège > Centre de recherches du cyclotron
Salmon, Eric  ;  Université de Liège - ULiège > Département des sciences cliniques > Neuroimagerie des troubles de la mémoire et révalid. cogn.
Luxen, André ;  Université de Liège - ULiège > Département de chimie (sciences) > Laboratoire de chimie organique de synthèse
Plenevaux, Alain  ;  Université de Liège - ULiège > Département de chimie (sciences) > Département de chimie (sciences)
Language :
English
Title :
EPILEPSY AND THE SV2A PROTEIN: new insights about the disease.
Publication date :
13 September 2018
Event name :
20TH EURON PhD DAYS
Event organizer :
European Graduate School of Neuroscience
Event place :
Leuven, Belgium
Event date :
13-14 septembre 2018
Audience :
International
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Available on ORBi :
since 04 January 2019

Statistics


Number of views
59 (6 by ULiège)
Number of downloads
14 (2 by ULiège)

Bibliography


Similar publications



Contact ORBi